Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Biologics such as Cinryze require processing steps that are more difficult than those required for most chemical pharmaceuticals, and as such we cannot assure you that the industrial scale process will be considered by the FDA to be equivalent to our existing manufacturing process. The FDA may view the data regarding equivalence of the industrial scale manufacturing process as insufficient or inconclusive, request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2010, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationCon
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Transfection Technology Market - Global Industry Analysis, Size, Share, ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... nucleic acids (either DNA or RNA) into cells. This ... of cancer cells and protein metabolism by affecting the ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Role of Chairman of the Board - , , ... INSM ), a biopharmaceutical company, today announced that Geoffrey Allan, ... Chairman of the Board of Directors, effective immediately, due to ... President, Chief Executive Officer and Chairman of the Board since ...
... , , , PHILADELPHIA, June 15 ERT ... and eClinical technology, ePRO, and other services to the biopharmaceutical, medical ... its portfolio of products and services at Booth #507 at the ... , , ERT will be showcasing, for the first ...
... returns to Paris for 2010 when, with ICSE, PMEC and BioPh, the ... on Tuesday 5 - Thursday 7 October. This is a week earlier ... to the dates of the last staging in Paris ... the quartet of co-located events to rival the 25,000+ attendees expected this ...
Cached Biology Technology:Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 2ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 3Paris Dates for CPhI Worldwide 2010 2
(Date:7/14/2014)... protein, discovered in 2005, controls T-cell activation and ... In doing so, it helps to guarantee immunological ... own structures that can lead to autoimmune disease. ... affect between five and ten per cent of ... of complex environmental influences when a genetic predisposition ...
(Date:7/14/2014)... 140 years ago, Charles Darwin noticed something peculiar about ... are more tame, and they also tend to display ... patches of white fur, and more juvenile faces with ... pattern has proved elusive, but now, in a Perspectives ... new hypothesis has been proposed that could explain why ...
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
Breaking Biology News(10 mins):Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2Domestication syndrome: White patches, baby faces and tameness 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... Florida State University marine biologist David L. Kimbro will ... in a massive effort to study the health and ... estuaries spanning 1,000 miles of Atlantic and Gulf of ... June 1, has become even more vital now following ...
... fluent in English whose first language is Chinese retrieve their ... in the June 2 issue of The Journal of ... second language in adolescence or later recall the sounds of ... study, Yan Jing Wu, PhD, and Guillaume Thierry, PhD, of ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-tio060110.php,">Chinese . ... of Medicine, in New Orleans, LA, have demonstrated ... seed oil ( Nigella sativa ) can suppress ... cell lines, in vitro. Although previous studies ...
Cached Biology News:Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 2Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 3Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 4Second language learners recall native language when reading 2Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2